← pool

📈 Retatrutide: Lilly's premium peptide upgrade path

Retatrutide's triple-agonist phase-3 data (37lb loss, liver fat -80%, A1C 7.9→6.0, muscle-sparing) makes it the premium upgrade above $50-Medicare tirzepatide — 'the Mercedes to the Honda... that's where they're going to start to make all this money' — with approval possibly late 2026, mid-2027 latest, and an 'avalanche of peptides' expanding the market beyond obesity into fitness and longevity.

Plays

Mention log newest first

Friedberg equities 43% · n=123 · E271 (2026-05-01) · explicit_prediction · strength 2 ▶ 1:03:46 SUPPORT

“for 50 bucks. But if you want to upgrade, get the Retatrutide, that's the high premium product. And that's where they're going to start to make all this money. That'll be the Mercedes to the Honda.”

Chamath equities 42% · n=163 · E271 (2026-05-01) · sentiment · strength 1 ▶ 1:02:13 SUPPORT

“it just looks like a wonder drug. I can't wait. ... It just feels like we're about to have an absolute avalanche of peptides to choose from.”

Who built this conviction

each voice's total push on the score, in conviction points across every mention — supports and opposes · share = % of all mention-driven movement

Friedberg 43%

1 scoring event · 75% of moves

+35.0 → net +35.0

Chamath 42%

1 scoring event · 25% of moves

+11.7 → net +11.7

⏳ decay drained -29.9 over the idea's life — that's time passing, attributed to no one

Score events